Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

Review does not support use of ACEIs in dogs with preclinical MMVD
The study found that administration of ACEIs to dogs with preclinical MMVD and cardiomegaly results in little or no difference in the risk of developing congestive heart failure

Researchers review adverse events of angiotensin-converting enzyme inhibitor use.

The use of angiotensin-converting enzyme inhibitors (ACEIs) for managing preclinical myxomatous mitral valve disease (MMVD) in dogs results in little or no difference in the risk of developing conegestive heart failure, according to new research.

The study, published in the Journal of Small Animal Practice, is the first comprehensive systematic review and meta-analysis on the efficacy and adverse events of ACEIs for the condition, often seen in cavalier King Charles spaniels and dachshunds.

It found that administration of ACEIs to dogs with preclinical MMVD and cardiomegaly results in little or no difference in the risk of developing congestive heart failure and may result in little or no difference in cardiovascular-related and all-cause mortality. 

The study was conducted by researchers in Argentina, Italy, Austria and Chile, who set out to evaluate the efficacy of and adverse events from the administration of ACEIs, via a systematic review of published evidence conducted according to the Cochrane Handbook for Systematic Reviews of Interventions.

Certainty of evidence was assessed using the GRADE approach, and the main finding in relation to dogs with preclinical MMVD and cardiomegaly backed by a high certainty of evidence. The certainty of evidence relating to the efficacy of ACEI administration in dogs without cardiomegaly was low.

Dr Pablo Donati, corresponding author for the paper, commented: “In recent times, multiple clinical trials have provided fundamental information to veterinary cardiology. In the era of evidence-based medicine, systematic reviews and meta-analyses have emerged as a fundamental tool for clinical decision-making by gathering, appraising and summarizing the best available evidence. 

"It is the hope of the authors that this systematic review and meta-analysis helps in the decision-making process for the treatment of preclinical myxomatous mitral disease with angiotensin-converting enzyme inhibitors in dogs.” 

Nicola Di Girolamo, Editor of JSAP, added: “In line with other leading journals, the JSAP is prioritizing the publication of methodologically sound systematic reviews such as this one. However, our readers should be aware that the findings of systematic reviews should always be considered in light of their internal validity, i.e. the quality of the included studies, and their external validity, i.e. the generalizability of the included studied to the individual patient.”

Image (C) Dr Pablo Donati.


Become a member or log in to add this story to your CPD history

Avian flu outbreak at RSPB Minsmere

News Story 1
 RSPB Minsmere nature reserve in Suffolk has confirmed an outbreak of highly pathogenic avian influenza on its site. The coastal nature reserve has seen an increase in dead birds recently, and has said that it is 'extremely concerned' about the potential impacts on bird populations, with 2021 and 2022 seeing the largest ever outbreak in the UK.

In a statement, RSPB said: "We appreciate that it is distressing, for both visitors and staff, to see dead or dying birds at our site but we ask that if visitors see any dead or unwell birds, they do not touch or go near them and that they report it to us at our Visitor Centre during its opening hours, or by emailing us on outside of these times."  

Click here for more...
News Shorts
Moredun Foundation Award opens for applications

The 2022-2023 Moredun Foundation Award (MFA) is now open for members, with up to £2,000 available for successful applicants.

The MFA honours the contribution that education, teamwork, life experience, and travel have made to the understanding of cattle health and welfare. Through its charitable endeavours, Moredun offers its members the opportunity to pursue projects that support personal development.

The prize is open to a wide range of project applications, including those that include producing educational tools, conducting a small research project, or studying farming methods in other nations. For more information and to apply, visit